A staff member works on the production line making Lianhua Qingwen capsules at Shijiazhuang Yiling Pharmaceutical Co in Shijiazhuang, Hebei province. (Photo provided to chinadaily.com.cn)
Applications for registration in more countries are underway, including countries in the Middle East, Africa and Latin America, the company said.
Lianhua Qingwen was recommended in four versions of a treatment plan from the National Health Commission for treating COVID-19, the pneumonia associated with the novel coronavirus.
On April 12, the National Medical Products Administration approved adding mild symptoms of COVID-19 as indications for which Lianhua Qingwen is effective.
